FUTURE shines bright for secukinumab in psoriatic arthritis
24 Apr 2020
bởiAudrey Abella
The phase III FUTURE 2 trial has shown the ability of the bDMARD*, interleukin(IL)-17A inhibitor secukinumab to provide sustained improvements across multiple clinical domains in patients with psoriatic arthritis (PsA) with consistent safety over 5 years.
